ClinicalTrials.gg
TerminatedNCT05493501Updated May 2, 2024Results posted

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

A Phase 3 interventional study of Aumolertinib monotherapy and Osimertinib monotherapy in NSCLC, sponsored by EQRx International, Inc.. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-02.

Sponsored by EQRx International, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
The study is being closed based on corporate changes at EQRx and is not related to any efficacy or safety issues with aumolertinib.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Aumolertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR mutations. The reason for this study is to learn whether adding chemotherapy to a new investigational drug called aumolertinib helps to slow or stop cancer growth in people with EGFR mutation-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC). The study will compare this new combination of drugs to osimertinib, given alone. Aumolertinib given alone will also be used in the study, and it will be looked at in comparison with osimertinib given alone.

This is a randomized, open-label study with 3 different groups that are listed below. "Randomized" means the study treatment participants take will be chosen by chance (decided at random by a computer). "Open-label" means that the participant, the study doctor, and the Sponsor will know which study treatment each participant is receiving.

Participants will be randomly assigned to one of the following 3 treatment groups:

  • Group 1: Treatment with aumolertinib alone, taken orally (by mouth) as a pill once a day. Around 100 participants will be randomly assigned to this group.
  • Group 2: Treatment with aumolertinib taken orally as a pill once a day, in combination with chemotherapy given intravenously (IV; through a needle placed in a vein) on the schedule provided by the study doctor. Around 200 participants will be randomly assigned to this group.
  • Group 3: Treatment with osimertinib alone, taken orally as a pill once a day. Around 200 participants will be randomly assigned to this group.

Because there will be twice as many participants in Group 2 and Group 3 as in Group 1, the chance of a participant being randomly assigned to either of those groups is twice as likely as being assigned to Group 1.

Participants can continue to receive study treatment as long as they have not withdrawn consent, as long as they choose to continue to receive study treatment and are judged by their doctor to continue to receive clinical benefit from receiving the study treatment, and as long as no other study treatment and/or study discontinuation criteria are met .

02

Conditions studied

  • NSCLC
03

In context

Lead sponsor

EQRx International, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is at least 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place)
  2. Has confirmed NSCLC that is Stage IIIB, (Stage IVA or IVB), or recurrent, and which is not amenable to curative intent therapy.
  3. Tumor harbors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity-ex19del or L858R-either alone or in combination with other EGFR mutations (eg, G719X, exon 20 insertions, S7681, L861Q)
  4. Has performance status of 0, 1, or 2 at the time of enrollment.
  5. Has adequate organ function at the time of enrollment.
  6. Has of ≤ 470 ms
  7. Male participants must agree to use a highly effective method of and to refrain from donating sperm while receiving study treatment
  8. Female participants are eligible to participate if not pregnant or breastfeeding, and at least one of the following conditions applies: is not of OR is of childbearing potential and using a highly effective contraceptive method while receiving study treatment AND agrees not to donate eggs (ova, oocytes) during this period
  9. All female participants must have a negative serum or urine pregnancy test result within 48 hours prior to initiation of study drug dosing

Exclusion criteria

Exclusion Criteria:

  1. Is a candidate for curative intent therapy for the NSCLC diagnosis.
  2. Tumor has mixed small-cell and non-small-cell pathology.
  3. Has received prior systemic treatment for NSCLC. Prior chemotherapy or immunotherapy is permitted, provided that it was used for treatment of locoregional NSCLC as a component of curative intent therapy and administration was completed more than 6 months ago.
  4. Has nausea and vomiting, chronic gastrointestinal disease(s), inability to swallow the formulated product (percutaneous endoscopic gastrostomy tube administration may be allowed if tablets are not crushed), or a history of previous significant bowel resection-any of which would preclude adequate absorption of aumolertinib or osimertinib.
  5. Has active or past medical history of interstitial lung disease, drug-induced interstitial lung disease or radiation pneumonitis that required treatment
  6. Has evidence of active bacterial, viral, or fungal infection which would preclude safe enrollment, as assessed by the treating Investigator.
  7. Has significant concomitant condition, that in the Investigator's judgment would prevent the participant from receiving study treatment or being followed in this study, or which otherwise renders the participant inappropriate for the study.
  8. For participants in the aumolertinib monotherapy and aumolertinib with chemotherapy arms, use of strong inhibitors/inducers within 14 days before initial study drug dosing and use of grapefruit-containing products within 72 hours before initial study drug dosing is prohibited.
  9. Has a history of prolonged syndrome or Torsades de Pointes
  10. Has any abnormalities in rhythm, conduction, or morphology of resting , including evidence of QT prolongation (QTc >470 ms for males and >480 ms for females) or has any factor, including any current medication(s), known to increase the risk of QTc prolongation or the risk of arrhythmic events
  11. or allergy to aumolertinib or osimertinib or their
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Aumolertinib monotherapy

    Drug: Aumolertinib monotherapy

  • Experimental
    Aumolertinib + platinum-based doublet chemotherapy

    For adenocarcinoma, either: * Aumolertinib + cisplatin with pemetrexed, or * Aumolertinib + carboplatin with pemetrexed For squamous cell carcinoma, one of the following: * Aumolertinib + cisplatin or carboplatin with paclitaxel; * Aumolertinib + cisplatin or carboplatin with albumin-bound paclitaxel; or * Aumolertinib + cisplatin or carboplatin with gemcitabine

    Drug: Aumolertinib monotherapy · Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel · Drug: Nab paclitaxel · Drug: Gemcitabine

  • Active comparator
    Osimertinib monotherapy

    Drug: Osimertinib monotherapy

Interventions

  • Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.

    Also known as: EQ143, HS-10296

  • DrugOsimertinib monotherapy

    80 mg tablet administered orally, once daily

    Also known as: Tagrisso

  • Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy

    Also known as: Alimta

  • Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.

  • Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.

  • Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.

    Also known as: Taxol

  • Administered by IV Infusion given over 4 fixed cycles per prescribing information.

    Also known as: Abraxane, Albumin-bound paclitaxel

  • Administered by IV Infusion over 4 fixed cycles per prescribing information.

    Also known as: Gemzar

This study also gives Osimertinib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    PFS is defined as the time from date of randomization until date of disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to 5 years

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time from date of randomization until death from any cause.

    Time frame: Up to 6 years

  2. Objective Response Rate (ORR) as Assessed by BICR Per RECIST v1.1

    ORR is defined as proportion of participants who achieve a complete response or partial response at any time before progressive disease or initiating a subsequent anticancer therapy.

    Time frame: Up to 5 years

  3. Disease Control Rate (DCR) as Assessed by BICR Per RECIST v1.1

    DCR is defined as the proportion of participants who have a best overall response of complete response or partial response or stable disease.

    Time frame: Up to 5 years

  4. Tumor Growth Rate (TGR) as Assessed by BICR Per RECIST v1.1

    TGR is defined as the constant exponential growth rate estimated using the sum of longest diameters based on radiological tumor assessment per RECIST v1.1.

    Time frame: Up to 5 years

  5. Duration of Response (DOR) as Assessed by BICR Per RECIST v1.1

    DOR is defined as date of first response (complete response or partial response) until date of disease progression or death due to any cause, whichever occurs first

    Time frame: Up to 5 years

  6. Depth of Response (DepOR) as Assessed by BICR Per RECIST v1.1

    DepOR is defined as the relative change in target lesion tumor size (calculated as the sum of the longest diameters of the target lesions, in the absence of new lesions or progression of nontarget lesions) as compared to baseline.

    Time frame: Up to 5 years

  7. PFS as Assessed by the Investigator Per RECIST v1.1

    PFS is defined as the time from date of randomization until date of disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to 5 years

  8. ORR as Assessed by the Investigator Per RECIST v1.1

    ORR is defined as the proportion of participants who achieve a complete response or partial response at any time before disease progression or initiating a subsequent anticancer therapy.

    Time frame: Up to 5 years

  9. DCR as Assessed by the Investigator Per RECIST v1.1

    DCR is defined as the proportion of participants who have a best overall response of complete response or partial response or stable disease.

    Time frame: Up to 5 years

  10. TGR as Assessed by the Investigator Per RECIST v1.1

    TGR is defined as the constant exponential growth rate estimated using the sum of longest diameters based on radiological tumor assessment per RECIST v1.1.

    Time frame: Up to 5 years

  11. DOR as Assessed by the Investigator Per RECIST v1.1

    DOR is defined as date of first response (complete response or partial response) until the date of disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to 5 years

  12. DepOR as Assessed by the Investigator Per RECIST v1.1

    DepOR is defined as the relative change in target lesion tumor size (calculated as the sum of the longest diameters of the target lesions, in the absence of new lesions or progression of nontarget lesions) as compared to baseline.

    Time frame: Up to 5 years

  13. Quality of Life as Assessed by the National Cancer Institute Patient Reported Outcomes Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE) Questionnaire

    NCI PRO-CTCAE questionnaire responses are scored from 0 to 4, wherein lower values represent a better outcome. For this trial, the burden of symptoms that will be captured by this questionnaire comprises nausea, diarrhea, and rash.

    Time frame: Up to 5 years

  14. Rate of Circulating Tumor DNA (ctDNA) Clearance

    ctDNA clearance is defined as when a detectable EGFR mutation in ctDNA at baseline becomes undetectable or drops below a predetermined threshold. Rate of ctDNA clearance is defined as 100 × number of participants who are ctDNA-negative at 6 weeks divided by number of participants who are ctDNA-positive at baseline.

    Time frame: 6 weeks

  15. Plasma Concentration of Aumolertinib

    Plasma concentration is defined as the measured drug concentration of aumolertinib.

    Time frame: Up to approximately 5 months

  16. Plasma Concentration of Aumolertinib Metabolite

    Plasma concentration is defined as the measured drug concentration of aumolertinib metabolite.

    Time frame: Up to approximately 5 months

  17. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    This outcome will evaluate the incidence of participants with TEAEs, graded according to NCI CTCAE V5.

    Time frame: From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years

  18. Number of Participants With Serious Adverse Events (SAEs)

    This outcome will evaluate incidence of participants with SAEs, be graded according to NCI CTCAE V5.

    Time frame: From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years

  19. Number of Participants With Electrocardiogram (ECG) Abnormalities

    This outcome will evaluate incidence of participants with ECG abnormalities

    Time frame: From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years

  20. Number of Participants With Laboratory Abnormalities

    This outcome will evaluate incidence of participants with laboratory abnormalities, graded according to NCI CTCAE V5.

    Time frame: From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years

07

Results

Posted May 2, 2024

Participant flow

Participant flow — Overall Study
MilestoneAumolertinib MonotherapyAumolertinib + Platinum-based Doublet ChemotherapyOsimertinib Monotherapy
Started125
Completed000
Not completed125

Outcome measures

PrimaryProgression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

PFS is defined as the time from date of randomization until date of disease progression or death due to any cause, whichever occurs first.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

OS is defined as the time from date of randomization until death from any cause.

Time frame:
Up to 6 years

No measurements were reported for this outcome.

SecondaryObjective Response Rate (ORR) as Assessed by BICR Per RECIST v1.1

ORR is defined as proportion of participants who achieve a complete response or partial response at any time before progressive disease or initiating a subsequent anticancer therapy.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryDisease Control Rate (DCR) as Assessed by BICR Per RECIST v1.1

DCR is defined as the proportion of participants who have a best overall response of complete response or partial response or stable disease.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryTumor Growth Rate (TGR) as Assessed by BICR Per RECIST v1.1

TGR is defined as the constant exponential growth rate estimated using the sum of longest diameters based on radiological tumor assessment per RECIST v1.1.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryDuration of Response (DOR) as Assessed by BICR Per RECIST v1.1

DOR is defined as date of first response (complete response or partial response) until date of disease progression or death due to any cause, whichever occurs first

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryDepth of Response (DepOR) as Assessed by BICR Per RECIST v1.1

DepOR is defined as the relative change in target lesion tumor size (calculated as the sum of the longest diameters of the target lesions, in the absence of new lesions or progression of nontarget lesions) as compared to baseline.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryPFS as Assessed by the Investigator Per RECIST v1.1

PFS is defined as the time from date of randomization until date of disease progression or death due to any cause, whichever occurs first.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryORR as Assessed by the Investigator Per RECIST v1.1

ORR is defined as the proportion of participants who achieve a complete response or partial response at any time before disease progression or initiating a subsequent anticancer therapy.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryDCR as Assessed by the Investigator Per RECIST v1.1

DCR is defined as the proportion of participants who have a best overall response of complete response or partial response or stable disease.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryTGR as Assessed by the Investigator Per RECIST v1.1

TGR is defined as the constant exponential growth rate estimated using the sum of longest diameters based on radiological tumor assessment per RECIST v1.1.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryDOR as Assessed by the Investigator Per RECIST v1.1

DOR is defined as date of first response (complete response or partial response) until the date of disease progression or death due to any cause, whichever occurs first.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryDepOR as Assessed by the Investigator Per RECIST v1.1

DepOR is defined as the relative change in target lesion tumor size (calculated as the sum of the longest diameters of the target lesions, in the absence of new lesions or progression of nontarget lesions) as compared to baseline.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryQuality of Life as Assessed by the National Cancer Institute Patient Reported Outcomes Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE) Questionnaire

NCI PRO-CTCAE questionnaire responses are scored from 0 to 4, wherein lower values represent a better outcome. For this trial, the burden of symptoms that will be captured by this questionnaire comprises nausea, diarrhea, and rash.

Time frame:
Up to 5 years

No measurements were reported for this outcome.

SecondaryRate of Circulating Tumor DNA (ctDNA) Clearance

ctDNA clearance is defined as when a detectable EGFR mutation in ctDNA at baseline becomes undetectable or drops below a predetermined threshold. Rate of ctDNA clearance is defined as 100 × number of participants who are ctDNA-negative at 6 weeks divided by number of participants who are ctDNA-positive at baseline.

Time frame:
6 weeks

No measurements were reported for this outcome.

SecondaryPlasma Concentration of Aumolertinib

Plasma concentration is defined as the measured drug concentration of aumolertinib.

Time frame:
Up to approximately 5 months

No measurements were reported for this outcome.

SecondaryPlasma Concentration of Aumolertinib Metabolite

Plasma concentration is defined as the measured drug concentration of aumolertinib metabolite.

Time frame:
Up to approximately 5 months

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

This outcome will evaluate the incidence of participants with TEAEs, graded according to NCI CTCAE V5.

Time frame:
From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Serious Adverse Events (SAEs)

This outcome will evaluate incidence of participants with SAEs, be graded according to NCI CTCAE V5.

Time frame:
From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Electrocardiogram (ECG) Abnormalities

This outcome will evaluate incidence of participants with ECG abnormalities

Time frame:
From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years

No measurements were reported for this outcome.

SecondaryNumber of Participants With Laboratory Abnormalities

This outcome will evaluate incidence of participants with laboratory abnormalities, graded according to NCI CTCAE V5.

Time frame:
From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events were collected until the study reached early termination. Adverse events were collected from date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), approximately 8 months, 17 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aumolertinib Monotherapy0/1 (0%)0/1 (0%)1/1 (100%)
Aumolertinib + Platinum-based Doublet Chemotherapy0/2 (0%)0/2 (0%)2/2 (100%)
Osimertinib Monotherapy0/5 (0%)0/5 (0%)5/5 (100%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventAumolertinib MonotherapyAumolertinib + Platinum-based Doublet ChemotherapyOsimertinib Monotherapy
Abdominal pain upperGastrointestinal disorders0/12/20/5
DiarrhoeaGastrointestinal disorders1/10/23/5
NauseaGastrointestinal disorders1/12/21/5
FatigueGeneral disorders0/12/21/5
Pain in extremityMusculoskeletal and connective tissue disorders1/10/20/5
Dermatitis acneiformSkin and subcutaneous tissue disorders1/10/20/5
Gastro-oesophageal reflux diseaseGastrointestinal disorders0/11/20/5
VomitingGastrointestinal disorders0/11/20/5
Neutrophil count decreasedInvestigations0/11/21/5
Muscular weaknessMusculoskeletal and connective tissue disorders0/11/20/5

Baseline characteristics

Study terminated early, no participants completed the study, no participants were analyzed.

Age, Continuous
Age, Continuous(years)Aumolertinib MonotherapyAumolertinib + Platinum-based Doublet ChemotherapyOsimertinib MonotherapyTotal
Mean69 (69 to 69)71 (66 to 75)63 (52 to 74)66 (52 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)Aumolertinib MonotherapyAumolertinib + Platinum-based Doublet ChemotherapyOsimertinib MonotherapyTotal
Female1247
Male0011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aumolertinib MonotherapyAumolertinib + Platinum-based Doublet ChemotherapyOsimertinib MonotherapyTotal
Hispanic or Latino0011
Not Hispanic or Latino1247
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aumolertinib MonotherapyAumolertinib + Platinum-based Doublet ChemotherapyOsimertinib MonotherapyTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White1258
More than one race0000
Unknown or Not Reported0000
08

Study locations

8 sites
  • Highlands Oncology Group
    Springdale, Arkansas 72762, United States
  • Memorial Cancer Institute
    Hollywood, Florida 33021, United States
  • Memorial Cancer Institute
    Pembroke Pines, Florida 33028, United States
  • QCCA - Mission Blood & Cancer
    Des Moines, Iowa 50314, United States
  • Summit Health
    Florham Park, New Jersey 07932, United States
  • SCRI - Tennessee Oncology PLLC- Chattanooga
    Chattanooga, Tennessee 37404, United States
  • SCRI - Tennessee Oncology- Nashville
    Nashville, Tennessee 37203, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Aug 2023, 8 months.

Results were first posted in May 2024, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2022
First posted
Aug 9, 2022
StartActual
Dec 14, 2022
Primary completionActual
Aug 31, 2023
CompletionActual
Aug 31, 2023
Results first posted
May 2, 2024
Last update
May 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05493501
Lead sponsor
EQRx International, Inc.
Responsible party
Sponsor
First posted
Aug 9, 2022
Start date
Dec 14, 2022
Primary completion
Aug 31, 2023
Completion
Aug 31, 2023
Results posted
May 2, 2024
Last update
May 2, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aumolertinib

Start the discussion